Asia Fresh News

Asia Fresh Stories

Archive for January 16th, 2013

Kepner-Tregoe (KT) Helps Companies Achieve Higher Levels of Productivity and Quality Through Major Upgrade to Signature Learning Solution

leave a comment »

KT Problem Solving and Decision Making (PSDM) helps organizations resolve complex issues through Clear Thinking
PRINCETON, N.J./PRNewswire/ — Increased profits through higher productivity and quality as well as lower costs has long been considered the holy grail of operational excellence. Kepner-Tregoe, the global capability development and consulting company, helps organizations achieve all three through their newly upgraded KT Problem Solving and Decision Making (PSDM) solution.
(Logo: http://photos.prnewswire.com/prnh/20121114/MM13944LOGO)
Today, the Princeton, New Jersey based company announced significant enhancements to this landmark workshop that help companies develop their employees’ capabilities to effectively solve difficult problems, make better decisions, manage risk and seize opportunities. Featuring new tools and media designed to enhance an attendee’s engagement and ability to apply KT’s Clear Thinking processes, the update creates a highly engaging environment for learners across generations.
Some of the new features and benefits of the KT PSDM solution include:
Process modifications resulting from 55 years of testing and application that can be better leveraged for rapid on-the-job results;
Nearly three hours of the most current media formats including live-action video, illustrated motion-graphics and simulation to enhance the learning experience;
A library of twenty-five new and time-tested cases that tackle relevant issues and demonstrate powerful, real-world examples of KT Clear Thinking;
A mobile app available for Apple iOS and Android devices that supports the use of KT process after the workshop; and
Integrated QR codes and social media elements that direct participants to additional content that reinforces concepts and provides technique reminders.
“KT seems to have done a great job on the upgrade,” said Joel Beezhold, director of continuous improvement at Johnson Controls (JCI). “At JCI we use a lot of video while developing the capabilities of our employees, so we really appreciate the addition of the new video and media for the upgraded PSDM.”
The PSDM update is part of a larger strategy launched in November 2012 when Kepner-Tregoe announced the KT Clear Thinking vision to help clients “build a Thinking Organization” supported by its new global website that focuses on customer needs. KT Clear Thinking allows organizations to run more efficiently, improve quality and drive bottom-line results by developing high-quality employee thinking and issue resolution capabilities with support of coaching and consulting solutions to maximize return on investment.
“This investment perfectly complements the KT Clear Thinking vision,” said Ray Baxter, chief executive officer at Kepner-Tregoe. “Organizations looking to improve operational excellence, develop the next generation of leaders and sustain competitive advantage will achieve a high ROI from thinking processes that have proven their value across industries and functions.”
Baxter added, “The update to KT PSDM is critical to our customers’ ongoing success in dealing with the ever-increasing complexity of business. We allocated substantial resources to ensure we evaluated and accordingly modified every element of the KT Clear Thinking process and supporting technology so learners can quickly absorb advanced techniques and drive better on-the-job results. Our customers will achieve maximum and sustained value from their engagements with KT.”
Kepner-Tregoe processes are based on the work of Dr. Charles Kepner and Dr. Benjamin Tregoe, two researchers who conducted a study on breakdowns in decision making at the Strategic Air Command. They found that successful decision making by Air Force officers had less to do with seniority or career path and more with the thinking process of gathering, organizing and analyzing information before taking action. Their basic thesis, that organizations can be taught to think clearly, stands as strong today as when they founded Kepner-Tregoe.
About Kepner-Tregoe Inc.
Kepner-Tregoe (KT) provides capability development and consulting solutions across the world to help build Thinking Organizations that resolve the most pressing issues with clarity and confidence. Founded in 1958 based on ground-breaking research on how people think, solve problems and make decisions, Princeton-based Kepner-Tregoe is dedicated to helping organizations achieve Operational Excellence by improving quality, increasing efficiency and reducing costs. KT Clear Thinking is used at every level of client organizations: to implement strategy; achieve step-change improvements in operations; increase customer satisfaction in support organizations; and drive superior issue resolution throughout the organization. KT provides Clear Thinking for a complex world. For additional information, visit the company’s website at kepner-tregoe.com or their social media platforms on LinkedIn, Twitter, Facebook and YouTube.
Contact:
Brad Russell
Pierpont Communications for Kepner-Tregoe
830-358-3423
brussell@piercom.com
Source: Kepner-Tregoe, Inc.

Written by asiafreshnews

January 16, 2013 at 5:44 pm

Posted in Uncategorized

Morningstar to Distribute PR Newswire Content on its Asian Investment Sites

leave a comment »

HONG KONG /PRNewswire/ — Morningstar Asia, a subsidiary of independent investment research firm Morningstar, Inc., today announced it will distribute press release content from PR Newswire, a global provider of marketing and communications solutions, on Morningstar’s investment websites in Hong Kong, Taiwan, Singapore, Malaysia, and other Asia-Pacific regions.
“We’re pleased to augment our investing content with relevant Asian company news provided by PR Newswire to broaden the scope of investment information our users can attain from our websites,” said Nick Cheung, chief executive officer for Morningstar Asia.
Joshua B. Cohen, vice president, content licensing and distribution for PR Newswire, added, “We are glad to extend our reach within the financial community in Asia through our agreement with Morningstar Asia and the readership of the five investment websites that Morningstar Asia provides.”
PR Newswire’s press release content will be accessible on the home page of Morningstar’s Asian investment sites in Hong Kong, Taiwan, Singapore, Malaysia, and other Asia-Pacific regions.
About Morningstar Asia and Morningstar, Inc.
Morningstar Asia is a subsidiary of Morningstar, Inc., a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offers an extensive line of products and services for individuals, financial advisors, and institutions. Morningstar provides data on more than 385,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 8 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its registered investment advisor subsidiaries and has approximately US$195 billion in assets under advisement and management as of Sept. 30, 2012. The company has operations in 27 countries.
About PR Newswire
PR Newswire is the premier global provider of multimedia platforms that enable marketers, corporate communicators, sustainability officers, public affairs and investor relations officers to leverage content to engage with all their key audiences. Having pioneered the commercial news distribution industry 58 years ago, PR Newswire today provides end-to-end solutions to produce, optimize and target content — from rich media to online video to multimedia — and then distribute content and measure results across traditional, digital, mobile and social channels. Combining the world’s largest multi-channel, multi-cultural content distribution and optimization network with comprehensive workflow tools and platforms, PR Newswire enables the world’s enterprises to engage opportunity everywhere it exists. PR Newswire serves tens of thousands of clients from offices in the Americas, Europe, Middle East, Africa and the Asia-Pacific region, and is a UBM plc company.
(C)2013 Morningstar, Inc. All Rights Reserved.
Media Contact:
Cecilica Chung
+852-2973-4655
cecilica.chung@morningstar.com
Source: Morningstar Asia Limited

Written by asiafreshnews

January 16, 2013 at 5:19 pm

Posted in Uncategorized

Phoenix Cardiac Devices announces start of clinical trial in India and Europe to test BACE(TM) device for treatment of mitral regurgitation without open heart surgery

leave a comment »

Study to assess safety and efficacy with goal of obtaining CE Mark approval
CHICAGO /PRNewswire/ — Phoenix Cardiac Devices, Inc., a medical device company with a novel method of repairing leaky heart valves without open-heart surgery, has enrolled its first patient in a clinical trial aimed at achieving CE Mark approval in Europe.
The trial will assess the safety and efficacy of the BACE™ device, an adjustable tension band that encircles the heart and supports the mitral valve leaflets so they close properly to prevent the back flow of blood into the heart. Known as mitral regurgitation, the leakage of blood backward into the left atrium contributes to the development of congestive heart failure.
Previous studies of BACE, including a proof of concept study in 12 patients and a feasibility study in 14 patients, demonstrated a significant reduction in mitral regurgitation and no device-related serious adverse events following implantation. Results of the proof of concept study were published in the Australian journal, Heart, Lung and Circulation in December, 2009.
The current study will enroll 60 patients in India and Europe who have moderate to severe functional mitral regurgitation. Patients will undergo implantation of BACE, a device designed by a cardiothoracic surgeon to prevent many of the complications that occur with traditional surgical repair of mitral valves. Such complications are due, in part, to open-heart surgery, which requires temporarily stopping the heart and pumping blood through a heart lung by-pass machine during the procedure.
“Our device sits outside the heart, so there is no need to open the heart and no contact with blood flow, both of which are associated with an increased risk of thrombosis, stroke and infections,” said Jai Raman, MD, PhD, inventor of BACE.
“Moreover, BACE alleviates the root cause of functional mitral regurgitation – dilated and weakened heart muscle – whereas current surgical treatments focus on replacing or repairing valves that are structurally normal,” said Raman, professor of surgery, director of adult cardiac surgery, and surgical director of transplantation at Rush University Medical Center in Chicago.
Among its unique features, BACE can be remotely adjusted from an external port, and its efficacy can be assessed through real-time echocardiography, allowing for immediate adjustments in tension and pressure.
The goal of BACE is to provide a more effective and less invasive method of treating mitral regurgitation that reduces complications and thus lowers the risk of mortality, according to Gopal Muppirala, CEO and co-founder of Phoenix Cardiac Devices. As a closed heart procedure, implantation of BACE may also reduce operating times and hospital stays, resulting in significantly lower costs than with open-heart procedures.
“The current standard of care was developed nearly 40 years ago and, with the advances in technology, there is both an opportunity and a critical need for less invasive and more effective treatments,” Muppirala said.
About Phoenix Cardiac Devices
The mission of Phoenix Cardiac Devices, Inc. is to design, develop, and market innovative, patented technologies in the cardiac medical device field. The company’s first product, currently in human trials, is a device that treats functional mitral regurgitation. http://www.phoenixcardiac.com
Source: Phoenix Cardiac Devices, Inc.

Written by asiafreshnews

January 16, 2013 at 4:20 pm

Posted in Uncategorized

ChanTest goes beyond GLP to become first ion channel and GPCR CRO with cGMP testing c

leave a comment »

CLEVELAND /PRNewswire/ — ChanTest announced today the capability to perform a bioassay in conformance with current Good Manufacturing Practices (cGMP)*. The in vitro assay involves higher throughput Ussing chamber experiments for measuring inhibition of CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) chloride ion channel short circuit current, a measure of chloride ion secretion. ChanTest passed its first regulatory inspection related to this cGMP bioassay at the end of last month.
(Logo: http://photos.prnewswire.com/prnh/20120817/CL58977LOGO)
In 2000, ChanTest began initiating assays related to hERG potassium channels in accordance with FDA Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies (21 CFR Part 58). The new cGMP testing capability allows ChanTest to offer a unique service to the pharmaceutical and biotech industry. ChanTest will offer cGMP bioassays for release of natural products (i.e., botanicals) and any drug working via ion channels, GPCRs or transporter targets for which analytical testing is not possible.
Arthur “Buzz” Brown, M.D., Ph.D., CEO at ChanTest said, “ChanTest is extremely excited to bring this unique cGMP testing service to the pharma community. This means that we can now partner with pharma and biotech companies to bring safe medicines to market from the beginning to the very end of the drug development process.”
ChanTest offers screening service with the Ussing assay for important transporters targets. Ussing experiments involve measuring electrical currents across epithelial cells under voltage clamp conditions.
*Conformance:
United States Pharmacopeia (USP)
USP Chapter 1032; Design and development of biological assays
USP Chapter 1033; Biological assay validation

cGMP Compliance:
21 CFR Part 210 and 21CFR Part 211
About ChanTest – The Ion Channel Expert
ChanTest’s mission is to serve the drug discovery and development needs of customers worldwide with high-value solutions for ion channel and GPCR biology. Since its inception in 1998, the CRO has tested compounds for more than 500 global pharmaceutical and biotechnology companies and partners with them to speed the drug development process for the release of better, safer drugs. ChanTest offers integrated ion channel and GPCR services (GLP and non-GLP) and reagents; the company’s library of validated ion channel cell lines and nonclinical cardiac risk assessment service portfolio is the most comprehensive commercially available today. Because of ChanTest’s seminal role in the nonclinical cardiac safety field, along with the company’s uncompromising commitment to quality, ChanTest has been named the “most trusted and most used fee-for-service provider” for ion channel screening in an independent survey for the past several years. ChanTest is based in Cleveland, Ohio. For more information, e-mail info@chantest.com.
Chris Mathes, Ph.D.
Chief Commercial Officer
ChanTest Corporation
732-586-1073
cmathes@chantest.com
Source: ChanTest

Written by asiafreshnews

January 16, 2013 at 3:47 pm

Posted in Uncategorized